Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

51.9K
Overview
51.9K
Birth Control Methods01:22

Birth Control Methods

6.9K
Vasectomy is a surgical form of male sterilization that involves severing and sealing the vasa deferentia, preventing sperm from mixing with semen during ejaculation. Because a vasectomy does not impact the testes' ability to produce testosterone, hormone levels, libido, and sexual function generally remain unchanged. While vasectomy is highly effective in preventing pregnancy, with a success rate near 99.85%, rare cases of recanalization (spontaneous reconnection) can occur. Although...
6.9K
Cancer Vaccines01:30

Cancer Vaccines

1.1K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

10.5K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.5K
Target Cell Response to Hormones01:22

Target Cell Response to Hormones

5.8K
Hormones intricately bind to receptors on the surface or within target cells, initiating a cascade of cellular responses.
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
5.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Access to general practice: why policy must be rural-proofed.

The British journal of general practice : the journal of the Royal College of General Practitioners·2026
Same author

Rotavirus mucosal immunology: insights and research priorities from an international convening in Liverpool, March 2024.

NPJ vaccines·2026
Same author

<i>Streptomyces</i> GMR22 exhibits anti-<i>Porphyromonas gingivalis</i> activity and binding affinity toward gingipain K and dipeptidyl aminopeptidase IV.

Journal of Taibah University Medical Sciences·2026
Same author

A Hybrid Delphi-Inspired Expert-LLM Workflow for Efficient Evidence Screening in Systematic Reviews.

Studies in health technology and informatics·2026
Same author

Economic Evaluation of Adopting a Risk Score for Diabetes Screening in Indonesia.

Value in health regional issues·2026
Same author

Cellular immune responses 12 months after fractional or standard dose BNT162b2 booster vaccination in Mongolian adults.

Frontiers in immunology·2026

Related Experiment Video

Updated: Feb 14, 2026

Assays for the Specific Growth Rate and Cell-binding Ability of Rotavirus
10:49

Assays for the Specific Growth Rate and Cell-binding Ability of Rotavirus

Published on: January 28, 2019

9.4K

Human Neonatal Rotavirus Vaccine (RV3-BB) to Target Rotavirus from Birth.

Julie E Bines1, Jarir At Thobari1, Cahya Dewi Satria1

  • 1From the RV3 Rotavirus Vaccine Program, Murdoch Children's Research Institute (J.E.B., A.H., E.W., D.C., J.S., F.J., G.B., K.J.L., G.L.B., K.B., N.B.-S., D.P., R.F.B., C.D.K., J.P.B.), the Department of Paediatrics, University of Melbourne (J.E.B., D.C., K.J.L., G.L.B., R.F.B., C.D.K., J.P.B.), and the Department of Gastroenterology and Clinical Nutrition, Royal Children's Hospital Melbourne (J.E.B., J.S.), Parkville, the Departments of Paediatrics and of Epidemiology and Preventive Medicine, Monash University, and the Department of Infection and Immunity, Monash Children's Hospital, Clayton (J.P.B.), and Medicines Development for Global Health (A.H.) and Global BioSolutions (J.A.), Melbourne - all in Victoria, Australia; the Department of Pharmacology and Therapy (J.A.T.), the Pediatric Research Office, Department of Paediatrics (C.D.S., A.V.I., Y.S.), and the Department of Microbiology (H.N.), Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, and PT Bio Farma, Bandung (N.S.B.) - all in Indonesia; and the Bill and Melinda Gates Foundation, Seattle (C.D.K.).

The New England Journal of Medicine
|February 22, 2018
PubMed
Summary

A neonatal rotavirus vaccine (RV3-BB) administered at birth proved effective in preventing severe rotavirus gastroenteritis in Indonesian infants. The neonatal schedule showed a 75% efficacy, offering a promising strategy for early rotavirus prevention.

More Related Videos

Simplified Reverse Genetics Method to Recover Recombinant Rotaviruses Expressing Reporter Proteins
11:40

Simplified Reverse Genetics Method to Recover Recombinant Rotaviruses Expressing Reporter Proteins

Published on: April 17, 2020

9.4K
Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography
09:31

Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography

Published on: January 27, 2023

1.6K

Related Experiment Videos

Last Updated: Feb 14, 2026

Assays for the Specific Growth Rate and Cell-binding Ability of Rotavirus
10:49

Assays for the Specific Growth Rate and Cell-binding Ability of Rotavirus

Published on: January 28, 2019

9.4K
Simplified Reverse Genetics Method to Recover Recombinant Rotaviruses Expressing Reporter Proteins
11:40

Simplified Reverse Genetics Method to Recover Recombinant Rotaviruses Expressing Reporter Proteins

Published on: April 17, 2020

9.4K
Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography
09:31

Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography

Published on: January 27, 2023

1.6K

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Vaccinology

Background:

  • Rotavirus gastroenteritis is a significant global health concern, particularly in neonates.
  • Current rotavirus vaccine implementation faces barriers, necessitating novel administration strategies.
  • Early prevention through neonatal vaccination may overcome existing challenges in global rotavirus control.

Purpose of the Study:

  • To evaluate the efficacy of an oral human neonatal rotavirus vaccine (RV3-BB) in preventing rotavirus gastroenteritis.
  • To compare the efficacy of RV3-BB administered on a neonatal schedule versus an infant schedule.
  • To assess the safety and immunogenicity of RV3-BB in a randomized controlled trial.

Main Methods:

  • A randomized, double-blind, placebo-controlled trial was conducted in Indonesia.
  • Healthy newborns received RV3-BB or placebo on either a neonatal (birth, 8, 14 weeks) or infant (8, 14, 18 weeks) schedule.
  • Efficacy was assessed based on severe rotavirus gastroenteritis incidence in per-protocol and intention-to-treat populations.

Main Results:

  • The neonatal schedule demonstrated 75% efficacy against severe rotavirus gastroenteritis, compared to 51% for the infant schedule.
  • Combined efficacy for both schedules was 63% in the per-protocol analysis.
  • High vaccine response rates (94-99%) were observed, with similar adverse event profiles across groups. No early intussusception events were reported.

Conclusions:

  • The RV3-BB vaccine is efficacious in preventing severe rotavirus gastroenteritis when administered via neonatal or infant schedules in Indonesia.
  • The neonatal schedule shows particular promise for early and effective rotavirus prevention.
  • The study supports the potential of RV3-BB as a valuable tool in global rotavirus disease control efforts.